FTC sues Amgen-Horizon, raising questions about PBM role in drug costs

FTC sues Amgen-Horizon, raising questions about PBM role in drug costsFor You U.S. Sports Entertainment Life Money Tech Travel Opinion

Drugs and Medications

Add Topic

Industry analysts are skeptical that FTC Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by Trump.

Arthur Allen

KFF Health News

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

On May 16, the FTC sued to block the merger of drugmakers Amgen and Horizon Therapeutics, saying the tangled web of drug industry deal-making would enable Amgen to leverage the monopoly power of two top Horizon drugs that have no rivals.

Help Terms of Service Subscription Terms & Conditions Privacy Policy Your California Privacy Rights / Privacy Policy Our Ethical Principles Site MapDo Not Sell / Share / Target My InfoCookie Settings

© 2023 USA TODAY, a division of Gannett Satellite Information Network, LLC.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source